Beutel, Goodman & Co Ltd. EPRX — Eupraxia Pharmaceuticals

Ownership history in Beutel, Goodman & Co Ltd.  ·  5 quarters on record

AI Ownership Summary

Beutel, Goodman & Co Ltd. reported Eupraxia Pharmaceuticals (EPRX) in 5 quarterly 13F filings from 2025 Q3 through 2026 Q3. Peak portfolio weight reached 0.25% in 2026 Q3. The latest visible filing shows EPRX at 0.25% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this EPRX ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Beutel, Goodman & Co Ltd.'s position in Eupraxia Pharmaceuticals, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q3

EPRX was reported at 0.25% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.25% in 2026 Q3

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2025 Q3 to 2026 Q3

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

How Beutel, Goodman & Co Ltd. held EPRX — position size vs. price
% of Fund (quarterly)    EPRX price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 5 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q3 REDUCED — — — 3,529,124 -98,740 -2.7% 0.25% $32K 2026-11-04 $6.76
2026 Q2 REDUCED — — — 3,627,864 -38,601 -1.1% 0.18% $24K 2026-08-12 $6.48
2026 Q1 REDUCED — — — 3,666,465 -42,908 -1.2% 0.18% $26K 2026-05-15 $6.92
2025 Q4 REDUCED 8.6% -4.1% ✅ 3,709,373 -349,526 -8.6% 0.17% $27.9M 2026-02-13 $8.42
2025 Q3 INITIATED — — — 4,058,899 — — 0.14% $23.9M 2025-11-14 $6.56

FAQ About Beutel, Goodman & Co Ltd. and EPRX

These are the practical questions this page is built to answer before you even open the full history table.

How long has Beutel, Goodman & Co Ltd. reported owning EPRX?

Beutel, Goodman & Co Ltd. reported EPRX across 5 quarterly 13F filings, from 2025 Q3 through 2026 Q3.

What was the largest reported EPRX position in Beutel, Goodman & Co Ltd.'s portfolio?

The largest reported portfolio weight for EPRX was 0.25% in 2026 Q3.

What is the latest reported EPRX position on this page?

The most recent filing on this page is 2026 Q3, when Beutel, Goodman & Co Ltd. reported 3,529,124 shares, equal to 0.25% of portfolio, with an estimated market value of $32K.

What does the chart on this EPRX ownership page compare?

The chart compares Beutel, Goodman & Co Ltd.'s quarterly EPRX portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Beutel, Goodman & Co Ltd. time their EPRX position?

Based on 13F filing dates vs. subsequent EPRX price moves, Beutel, Goodman & Co Ltd. correctly timed 3 out of 4 reported position changes (75%). The annualised alpha on EPRX relative to SPY over the holding period was -11.0%.

← Back to Beutel, Goodman & Co Ltd. Holdings